Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the Prostate Cancer Awareness Month edition of ZERO's Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, and survivorship has been pulled from the headlines and delivered to your inbox. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Treatment Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with BRCA2 alterations. » Full Article on The ASCO Post Diagnostics 64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer The FDA has granted fast-track designation to 64Cu-SAR-bisPSMA for use in the positron emission tomography (PET) imaging of patients with prostate-specific membrane antigen (PSMA)positive prostate cancer lesions with suspected metastasis. » Full Article on OncLive Treatment CCR Score to Predict ADT Benefit in Men with Prostate Cancer This podcast discussed how the Cell Cycle Risk (CCR) Score was used to determine the benefit of ADT in men with prostate cancer. » Full Article and Podcast at ASCO Publications Treatment Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer Researchers aimed to identify trends in active surveillance over a 10-year span, including overall utilization, age, Gleason score, level of education, and various other factors. » Full Article at JAMA Network Diagnostics U.S. Food and Drug Administration Approves FoundationOne® CDx and FoundationOne® Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer The FDA has approved FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for AstraZeneca's and Merck's Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). » Full Article at Foundation Medicine Diagnostics Multicancer early detection blood test preferentially detects high-grade prostate cancer A multi-cancer early detection blood test was reviewed and found to detect high-grade, clinically significant prostate cancer without overdetection of indolent disease. » Full Article from the Urology Times Treatment Olaparib Without ADT Benefits HRR-Mutated High-Risk Recurrent Prostate Cancer Researchers studied PARP inhibitor, olaparib, without the use of ADT, following a radical prostatectomy and found the medication was especially beneficial for patients with BRCA2 alterations. » Full Article from Renal+Urology News Health Equity Prostate-Specific Antigen Screening in Transgender Patients A review of publications was performed to better understand trends and patterns in prostate cancer screening, incidence, and care in transgender women. » Full article from National Library of Medicine ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or the recommendations of your healthcare team. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the Prostate Cancer Awareness Month edition of ZERO's Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, and survivorship has been pulled from the headlines and delivered to your inbox. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Treatment Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with BRCA2 alterations. » Full Article on The ASCO Post Diagnostics 64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer The FDA has granted fast-track designation to 64Cu-SAR-bisPSMA for use in the positron emission tomography (PET) imaging of patients with prostate-specific membrane antigen (PSMA)positive prostate cancer lesions with suspected metastasis. » Full Article on OncLive Treatment CCR Score to Predict ADT Benefit in Men with Prostate Cancer This podcast discussed how the Cell Cycle Risk (CCR) Score was used to determine the benefit of ADT in men with prostate cancer. » Full Article and Podcast at ASCO Publications Treatment Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer Researchers aimed to identify trends in active surveillance over a 10-year span, including overall utilization, age, Gleason score, level of education, and various other factors. » Full Article at JAMA Network Diagnostics U.S. Food and Drug Administration Approves FoundationOne® CDx and FoundationOne® Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer The FDA has approved FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for AstraZeneca's and Merck's Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). » Full Article at Foundation Medicine Diagnostics Multicancer early detection blood test preferentially detects high-grade prostate cancer A multi-cancer early detection blood test was reviewed and found to detect high-grade, clinically significant prostate cancer without overdetection of indolent disease. » Full Article from the Urology Times Treatment Olaparib Without ADT Benefits HRR-Mutated High-Risk Recurrent Prostate Cancer Researchers studied PARP inhibitor, olaparib, without the use of ADT, following a radical prostatectomy and found the medication was especially beneficial for patients with BRCA2 alterations. » Full Article from Renal+Urology News Health Equity Prostate-Specific Antigen Screening in Transgender Patients A review of publications was performed to better understand trends and patterns in prostate cancer screening, incidence, and care in transgender women. » Full article from National Library of Medicine ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or the recommendations of your healthcare team. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
